Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma
Open Access
- 6 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (2), 307-319
- https://doi.org/10.1158/1535-7163.mct-20-0525
Abstract
Relapsed pediatric rhabdomyosarcomas (RMS) and neuroblastomas (NBs) have a poor prognosis despite multimodality therapy. In addition, the current standard of care for these cancers includes vinca alkaloids that have severe toxicity profiles, further underscoring the need for novel therapies for these malignancies. Here, we show that the small-molecule rigosertib inhibits the growth of RMS and NB cell lines by arresting cells in mitosis, which leads to cell death. Our data indicate that rigosertib, like the vinca alkaloids, exerts its effects mainly by interfering with mitotic spindle assembly. Although rigosertib has the ability to inhibit oncogenic RAS signaling, we provide evidence that rigosertib does not induce cell death through inhibition of the RAS pathway in RAS-mutated RMS and NB cells. However, the combination of rigosertib and the MEK inhibitor trametinib, which has efficacy in RAS-mutated tumors, synergistically inhibits the growth of an RMS cell line, suggesting a new avenue for combination therapy. Importantly, rigosertib treatment delays tumor growth and prolongs survival in a xenograft model of RMS. In conclusion, rigosertib, through its impact on the mitotic spindle, represents a potential therapeutic for RMS.Keywords
Other Versions
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIA BC011805)
- National Cancer Institute National Institutes of Health (75N91019D00024)
This publication has 55 references indexed in Scilit:
- ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative StressClinical Cancer Research, 2012
- Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic CancerClinical Cancer Research, 2012
- High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastomaEuropean Journal of Cancer, 2011
- Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosisFree Radical Biology & Medicine, 2010
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010
- Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803Journal of Clinical Oncology, 2009
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2004
- Pyridinylimidazole Compound SB 203580 Inhibits the Activity but Not the Activation of p38 Mitogen-Activated Protein KinaseBiochemical and Biophysical Research Communications, 1999